Dynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatment
Author
Provencio Pulla, Mariano; Torrente, María; Calvo de Juan, Virginia; Gutiérrez, Lourdes; Pérez-Callejo, David; Pérez-Barrios, Clara; Barquín, Miguel; Royuela Vicente, Ana; Rodríguez-Alfonso, Begoña; Sotelo, Miguel; Cruz-Bermúdez, Juan Luis; Mendez, Miriam; Cruz-Bermúdez, Alberto; Romero, AtochaEntity
UAM. Departamento de MedicinaPublisher
Impact JournalsDate
2017-08-07Citation
10.18632/oncotarget.20016
Oncotarget 8.36 (2017): 60291-60298
ISSN
1949-2553DOI
10.18632/oncotarget.20016Funded by
This study was supported by Carlos III Institute of Health, Spanish Ministry of Science and Innovation, and European Regional Development Fund (grant number: PI16/01818 and PIE14/00064), A Romero is supported by Joan Rodés fellowship (grant number: JR14/00017) and CP pre-doctoral studies are supported by Jose Luís Castaño FoundationProject
Gobierno de España. PI16/01818; Gobierno de España. PIE14/00064Editor's Version
http://doi.org/10.18632/oncotarget.20016Subjects
cfDNA; TKI; Personalized medicine; Lung cancer; Liquid biopsy; MedicinaRights
© 2017 Provencio et al.Abstract
Background: Liquid biopsy has evolved from being a promising line to becoming
a validated approach for biomarker testing. However, its utility for individualization of
therapy has been scarcely reported. In this study, we show how monitoring levels of
EGFR mutation in plasma can be useful for the individualization of treatment.
Results: Longitudinal EGFR mutation levels in plasma always correlated with
tumor response ascertained by RECIST criteria. Moreover, decreasing EGFR mutation
levels were detected in all patients benefiting from locoregional radiotherapy, whereas
the opposite occurred when a patient progressed soon after radiotherapy treatment.
Similarly, increasing EGFR mutation levels anticipated disease progression after TKI
dose reduction, discontinuation of treatment, or reduced bioavailability due to drug
interactions. In addition, EGFR mutation levels were useful to monitor treatment
outcome of new therapies and constituted a decisive factor when the clinical situation
of the patient did not correlate with responses ascertained by radiologist. Finally, our
results indicate that cancer associated body fluids (pleural, pericardial or cerebrospinal
fluid) are certainly a suitable source for biomarker testing that can extend EGFR mutation
detection to biofluids other than blood.
Materials and Methods: A total of 180 serial plasma samples from 18 non-smallcell
lung cancer patients who carried an activating EGFR mutation were investigated
by digital PCR.
Conclusions: Monitoring levels of EGFR mutation in plasma allows resolving doubts
that frequently arise in daily clinical practice and constitutes a major step towards
achieving personalized medicine
Files in this item
Google Scholar:Provencio Pulla, Mariano
-
Torrente, María
-
Calvo de Juan, Virginia
-
Gutiérrez, Lourdes
-
Pérez-Callejo, David
-
Pérez-Barrios, Clara
-
Barquín, Miguel
-
Royuela Vicente, Ana
-
Rodríguez-Alfonso, Begoña
-
Sotelo, Miguel
-
Cruz-Bermúdez, Juan Luis
-
Mendez, Miriam
-
Cruz-Bermúdez, Alberto
-
Romero, Atocha
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients
Provencio Pulla, Mariano; Pérez-Callejo, David; Torrente, María; Martín, Paloma; Calvo de Juan, Virginia; Gutiérrez, Lourdes; Franco, Fernando; Coronado, María José; Cruz-Bermúdez, Juan Luis; Martín Ruiz-Valdepeñas, Asunción; Cruz-Bermúdez, Alberto; Sánchez-Beato, Margarita; Romero, Atocha; García-Grande, Aránzazu
2017-07-31 -
KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor
Serna-Blasco, R.; Sánchez-Herrero, E.; Sanz-Moreno, S.; Rodriguez-Festa, A.; García-Veros, E.; Casarrubios, M.; Sierra-Rodero, B.; Laza-Briviesca, R.; Cruz-Bermúdez, A.; Mielgo-Rubio, X.; Sánchez-Hernández, A.; Uribelarrea, E. A.; Calvo de Juan, Virginia; Romero, A.; Provencio Pulla, Mariano
2021-10-01 -
Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition
Cruz-Bermúdez, Alberto; Laza-Briviesca, Raquel; Vicente-Blanco, Ramiro J.; García-Grande, Aránzazu; Coronado, Maria José; Laine Menéndez, Sara; Palacios-Zambrano, Sara; Moreno-Villa, M. Rocío; Martín Ruiz-Valdepeñas, Asunción; Lendinez, Cristina; Romero, Atocha; Franco, Fernando; Calvo de Juan, Virginia; Alfaro, Cristina; Martín Acosta, Paloma; Salas, Clara; Garcia, José Miguel; Provencio Pulla, Mariano
2019-05-14